VIRAL HEPATITIS

HCV-infected lungs and hearts can be safely transplanted into non-infected individuals

The transplantation of organs from donors with hepatitis C viraemia is typically avoided, but the advent of direct-acting antiviral (DAA) agents could prevent transmission of HCV to the recipient and enable the use of HCV-infected organs. In a US-based open label trial, 44 patients without HCV infection received organ transplantations (36 lungs, 8 hearts) from HCV-infected donors, immediately followed by a 4-week regimen of a pangenotypic DAA agent. Of the 35 patients with at least 6 months of follow-up, all had excellent graft function with a sustained undetectable hepatitis C viral load from ~2 weeks after transplantation. Thus, this approach of preventing establishment of HCV infection with DAA therapy could increase the available donor organ pool.

References

Original article

  1. Woolley, A. E. et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1812406 (2019)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Iain Dickson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. HCV-infected lungs and hearts can be safely transplanted into non-infected individuals. Nat Rev Gastroenterol Hepatol 16, 326 (2019). https://doi.org/10.1038/s41575-019-0154-6

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing